APGE vs TENX
APGE: Apogee Therapeutics is a clinical-stage biotechnology firm developing advanced biologic therapies for inflammatory and immunology diseases, currently pending acquisition by AbbVie. TENX: Tenax Therapeutics is a clinical-stage biotechnology company developing specialized therapies for pulmonary hypertension and other cardiopulmonary conditions.
Side-by-side fundamentals
| Metric | APGE | TENX | Edge |
|---|---|---|---|
| Price as of 2026-08-10 close | $134.65 | $13.44 | |
| Market cap as of 2026-08-11 | $10.2B | $356M | |
| PEG as of 2026-08-11 | -1.41 | -0.15 | APGE lower |
| Net margin as of 2026-08-11 | n/a | -10115.8% | |
| Gross margin as of 2026-08-11 | n/a | +100.0% | |
| Operating margin as of 2026-08-11 | n/a | -10390.5% | |
| ROE as of 2026-08-11 | -32.6% | -56.3% | APGE higher |
| ROA as of 2026-08-11 | -31.3% | -53.1% | APGE higher |
| Debt / equity as of 2026-08-11 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-08-11 | n/a | -82.9% | |
| Beta as of 2026-08-11 | 0.21 | 0.89 | |
| 1-year return as of 2026-08-10 close | +280.5% | +124.7% | APGE higher |
Fundamentals: market data, as of 2026-08-11. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.